FGFR3 mutation

Absolutely but isn't it odd that we have trials of agents that can circumvent fgfr3 gatekeeper mutations when there are no public reports of this resistance mechanism in bladder cancer? (@ResearchWyatt)

Highlight Article: FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias https://t.co/ud5gtxUnrH @uroDr_mjShi @JFontugne @dr_xmeng @cs_groen et al. #bladder #urology (@EUplatinum)

January 2023 Issue FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias https://t.co/ud5gtxTPC9 (@EUplatinum)

Dr. Campbell on promise of infigratinib in FGFR3 mutation–positive UTUC https://t.co/gXaB6hc2Sp #urology #urologist #UTUC #urothelialcancer @MDAndersonNews (@UrologyTimes)

FGFR3 mutations in Upper Tract #urothelialcarcinoma-earlier stage, better survival (not DFS) after radical surgery-study by Alessandro Rizzo @fmassari79-PROOF302 phase III ongoing-adjuvant infigratinib v placebo @montypal @siadaneshmand https://t.co/PTq4a25zZn @practiceupdate (@sonpavde)

FGFR3 mutation modestly associated with favorable outcomes-#bladdercancer after #cystectomy-study from @NKI_nl-comment @LuisMezaco-Please support PROOF-302 trial evaluating adjuvant FGFR inhibition in this group @montypal @siadaneshmand https://t.co/gvnmUDDzvT @practiceupdate (@sonpavde)

Fgfr3 and her2 mutaitional exclusivity? Interessenting perspektive in UC!#ASCOGU22 (@IvanyiPhilipp)

Very nice case @clearyonc @GIcancerDoc I am particularly interested if FGFR inhibitors help conditions like craniosynostosis. Preclinical data with infigratinib and achondroplasia (activating FGFR3 mutation) led to Propel trial https://t.co/vvx2V8b4Hx #achondroplasia #dwarfism (@JavleMilind)

⚡️ Artificial Intelligence–based Detection of FGFR3 Mutational Status Directly from Routine Histology in #BladderCancer: A Possible Preselection for Molecular Testing? https://t.co/QuPjFcvSw7 (@drenriquegrande)

Happy to see the first patient w high-risk #urothelialcarcinoma and FGFR3 mutation enrolled into the adjuvant pemigatinib ph 2 trial #PEGASUS @EAUrf @Uroweb @MyUniSR @SanRaffaeleMI (@AndreaNecchi)

Genomic + epigenomic profiling of upper tract #urothelialcarcinoma-2 methylome subtypes-1) enriched for non-MI (muscle-invasive)-hypomethylated, immune-depleted, FGFR3 mutations; 2) MI-hypermethylated, immune-infiltrated, SWI/SNF mutations https://t.co/eKelw1BLzJ @practiceupdate (@sonpavde)

FGFR3 mutations associated With lower Sensitivity to Platinum-Based #Chemo in #UrothelialCarcinoma-appears more relevant in peri-operative (lower pCR, lower RFS) than metastatic setting (lower ORR but not PFS,OS)-from @MTeoMD @IyerGopa https://t.co/CAJxWoUUDx @practiceupdate (@sonpavde)

Strong start to #IBCN2020 with State-of-the-Art overview on role of FGFR3 mutations in #BladderCancer by François Radvanyi. @IBCN1997 @UroToday @MDAndersonNews @IBCG_BladderCA @WorldBladderCan @UroDocAsh @pcvblack @SWilliams_MD @Roland3097 @LDyrskjot @docmeetings (@APMitra)

NGS of Urothelial cancer especially UTUC and papillary NMIBC important for targeted Rx and FGFR3 mutations These may be immune quiescent and benefit from combination Rx #gdsfellows @NYUUrology #bladdercancer @BCAN_NCT (@garysteinbergmd)

A majority favor the Javelin Bladder 100 paradigm of gem-platinum followed by switch maintenance Avelumab for metastatic #UrothelialCarcinoma with somatic FGFR3/2 activating mutations/fusions-should we study switch maintenance FGFR inhibitor in this population? (@sonpavde)

Sequencing therapy for metastatic #UrothelialCarcinoma:question to members of @asco @myESMO @BladderCancerUS:In post-platinum & PD1/L1 inh pts with FGFR3/2 mutations/fusions-if no contraindications/patient preferences for Erdafitinib or Enfortumab Vedotin, I advise initial: (@sonpavde)

And Infigratinib in metastatic urothelial carcinoma harboring FGFR3 mutations - a solid 22% ORR in bladder cancer and 50% in UTUC (n=8). Maybe a role in UTUC? Would love to see more work about specific mutations and response! @DanielPetrylak @montypal @MattGalsky (@DrTylerStewart)

New original article by @montypal et al reveals that infigratinib demonstrated activity in metastatic urothelial carcinoma (UC) bearing FGFR3 mutations/fusions, with particular activity in upper tract UC. https://t.co/6PWhPBHlVM #uroonc (@JournalCancer)

The trial required documentation of mutation in FGFR3 or fusion of FGFR2/3. Luminal 1 subtype which is less responsive to checkpoint inhibitors and has more frequent FGFR mutations might respond better to Erdafitinib. #bladdercancer #immunotherapy @BladderCancerMD (@anandoncologist)